My laboratory is involved in studies to genetically modify autologous lymphocytes to improve their anti-tumor activity. In 1990 we reported the first studies of gene transfer in humans which involved the adoptive transfer of TIL transduced with a marker gene encoding neomycin phosphotransferase. These studies suggested the possibility that genes could be inserted into lymphocytes to improve their anti-tumor efficacy. We have now made progress in this area by developing techniques for the high efficiency transduction of human lymphocytes. The genes encoding high affinity anti-tumor T cell receptors (TCR) that recognize antigens on melanomas and common epithelial cancers have been identified and clinical trials to use autologous T cells transduced with these TCRs have begun. In recent studies we have shown that up to 30% of patients with metastatic melanoma will achieve objective clinical cancer regressions when treated with their autologous lymphocytes that have been transduced with T cell receptors that recognized the MART-1 or gp100 melanoma antigens. T cell receptors have now been identified that recognize NY-ESO-1, MAGE-A3, and CEA epitopes. Chimeric antigen receptors have been developed that recognize CD19 cell surface antigens on B cell malignancies and the EGFRvIII mutation expressed on glioblastomas. Clinical trials are being performed to study the treatment of patients with a variety of cancer types using these transduced cells. Multiple patients treated with cells transduced with a chimeric receptor targeting CD19 have had substantial responses. 80% of patients treated have had objective responses in the absence of IL-2 administration. Using cells transduced with a TCR reactive with the NY-ESO-1 cancer testes antigen 10 of 19 melanoma patients and 10 of 15 synovial cell sarcoma patients have had objective responses.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC010985-09
Application #
9343763
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
9
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Jin, Benjamin Y; Campbell, Tracy E; Draper, Lindsey M et al. (2018) Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. JCI Insight 3:
Rossi, John; Paczkowski, Patrick; Shen, Yueh-Wei et al. (2018) Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. Blood 132:804-814
Qutob, Nouar; Masuho, Ikuo; Alon, Michal et al. (2018) RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells. Sci Rep 8:653
Kochenderfer, James N; Somerville, Robert P T; Lu, Tangying et al. (2017) Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. Mol Ther 25:2245-2253
Qiao, Guilin; Qin, Jianzhong; Kunda, Nicholas et al. (2017) LIGHT Elevation Enhances Immune Eradication of Colon Cancer Metastases. Cancer Res 77:1880-1891
Parkhurst, Maria; Gros, Alena; Pasetto, Anna et al. (2017) Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression. Clin Cancer Res 23:2491-2505
Rosenberg, Steven A; Tran, Eric; Robbins, Paul F (2017) T-Cell Transfer Therapy Targeting Mutant KRAS. N Engl J Med 376:e11
Deniger, Drew C; Pasetto, Anna; Tran, Eric et al. (2016) Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System. Mol Ther 24:1078-89
Jaigirdar, Adnan; Rosenberg, Steven A; Parkhurst, Maria (2016) A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells. J Immunother 39:105-16
Klebanoff, Christopher A; Rosenberg, Steven A; Restifo, Nicholas P (2016) Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med 22:26-36

Showing the most recent 10 out of 86 publications